Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.

DLQI 0/1 Response by Psoriasis Area and Severity Index (PASI), Investigator’s Global Assessment (IGA), and PSSD Responses Stratified by the improvement in PASI, IGA, and PSSD scores, our analysis showed a clear trend indicating that greater improvement in psoriasis severity was associated with greater improvement in DLQI 0/1.

also in 19,460 other papers